Irhythm Technologies, INC

iRhythm Holdings, Inc. reported a material cybersecurity incident involving unauthorized access to third-party hosted applications, with a threat actor claiming to possess sensitive data.

iRhythm Technologies has reached a $45 million settlement to resolve a pending class action securities lawsuit.

iRhythm Holdings stockholders approved the 2026 Equity Incentive Plan and ratified the appointment of KPMG LLP at the 2026 Annual Meeting.

iRhythm Holdings, Inc. announced the appointment of Jason Patten, Executive Vice President at UnitedHealth Group, to its Board of Directors and Audit Committee, effective March 12, 2026.

iRhythm Holdings, Inc. reported strong fourth quarter and full year 2025 financial results, achieving record revenue and its first-ever quarter of positive GAAP net income.

iRhythm Technologies, Inc. announced a corporate reorganization into a holding company structure, provided strong preliminary Q4 2025 results, and issued an optimistic 2026 financial outlook.

iRhythm Holdings reports strong Q1 2026 revenue growth of 26% to $199.4 million, driven by increased demand for its ambulatory cardiac monitoring services.

iRhythm Technologies reported a significant reduction in net loss and strong revenue growth for the third quarter and first nine months of 2025, driven by increased demand for its cardiac monitoring services.

iRhythm Technologies, a digital healthcare company, reported significant revenue growth and improved profitability for the second quarter and first half of 2025, despite facing multiple ongoing legal proceedings and regulatory scrutiny.

iRhythm Technologies' Q1 2025 revenue increased by 20% year-over-year, reaching $158.7 million, despite ongoing legal proceedings and regulatory scrutiny.

iRhythm Technologies' Q3 2024 results show a significant increase in revenue and strategic investments, alongside a net loss impacted by research and development expenses.

iRhythm Technologies' second quarter 2024 results show a 19% increase in revenue compared to the same period last year, driven by increased demand for their Zio Services.

iRhythm Holdings, Inc. reported a 26% increase in revenue and a significantly reduced net loss for 2025, while navigating multiple ongoing legal and regulatory challenges.

iRhythm Technologies' 2024 10-K filing details the company's financial performance, strategic initiatives, and risk factors, highlighting its focus on cardiac monitoring solutions.

iRhythm Technologies' 2023 annual report reveals a 20% revenue increase alongside ongoing challenges in reimbursement and regulatory compliance.

Julianne Rodda, EVP, CHIEF PEOPLE OFFICER of iRhythm Technologies, Inc., sold 2,112 shares of common stock on August 3, 2026 for $122.12 per share.

Chad Patterson, CHIEF COMM & PRODUCT OFFICER of iRhythm Technologies, Inc., sold 2,712 shares of common stock on August 3, 2026 for $122.12 per share.

iRhythm Holdings executive Minang Turakhia sold 1,423 shares of common stock on July 2, 2026, for tax withholding purposes.

Sean Clinton Freeman of iRhythm Holdings, Inc. reported a sale of 918 common stock shares on July 2, 2026, for $124.71 per share.

iRhythm Holdings, Inc. reports a Form 4 filing detailing stock transactions by EVP, Chief Risk Officer Sumi Shrishrimal, including share acquisitions and sales for tax withholding.

iRhythm Holdings reports an acquisition of common stock by Chief Medical/Scientific Officer and EVP of Advanced Technology, Minang Turakhia, under the company's Employee Stock Purchase Plan.

iRhythm Holdings, Inc. announces its 2026 Annual Meeting of Stockholders to vote on director elections, a new equity incentive plan, and corporate governance amendments.

iRhythm Technologies, Inc. has filed a definitive proxy statement with the SEC pursuant to Section 14(a) of the Securities Exchange Act of 1934.

iRhythm Technologies invites stockholders to its virtual 2025 Annual Meeting on May 28, 2025, to vote on director elections, auditor ratification, and executive compensation.

iRhythm Technologies, Inc. will hold its 2024 Annual Meeting on May 29, 2024, where stockholders will vote on the election of directors, ratification of the company's accounting firm, executive compensation, and an amendment to the company's certificate of incorporation.

iRhythm Technologies is holding its 2024 Annual Meeting of Stockholders to vote on key proposals including the election of directors, ratification of the accounting firm, executive compensation, and an amendment to the company's charter.

RTW Investments, LP and Roderick Wong, M.D. have jointly filed a Schedule 13G, reporting beneficial ownership of 5.2% of iRhythm Holdings, Inc. common stock as of March 31, 2026.

Sands Capital Management and Frank M. Sands have filed an amendment indicating they no longer beneficially own any shares of iRhythm Holdings, Inc.

Vanguard Portfolio Management has reported beneficial ownership of 5.64% of iRhythm Holdings Inc.'s common stock as of March 31, 2026.

Vanguard Capital Management has filed a Schedule 13G reporting a 5.23% beneficial ownership stake in iRhythm Technologies, Inc.

The Vanguard Group filed an amendment to its Schedule 13G for IRhythm Holdings Inc., reflecting a change in its beneficial ownership reporting due to an internal realignment.

Millennium Management LLC, along with Millennium Group Management LLC and Israel A. Englander, has reported a 5.1% beneficial ownership stake in iRhythm Holdings, Inc.